Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies

In patients with primary antibody deficiencies, subcutaneous administration of IgG (SCIG) replacement is effective, safe, well-tolerated, and can be self-administered at home. A new SCIG replacement at 20% concentration (Hizentra(®)) has been developed and has replaced Vivaglobin(®) (SCIG 16%). An o...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Int J Immunopathol Pharmacol
Hauptverfasser: Canessa, Clementina, Iacopelli, Jessica, Pecoraro, Antonio, Spadaro, Giuseppe, Matucci, Andrea, Milito, Cinzia, Vultaggio, Alessandra, Agostini, Carlo, Cinetto, Francesco, Danieli, Maria Giovanna, Gambini, Simona, Marasco, Carolina, Trizzino, Antonino, Vacca, Angelo, De Mattia, Domenico, Martire, Baldassarre, Plebani, Alessandro, Di Gioacchino, Mario, Gatta, Alessia, Finocchi, Andrea, Licciardi, Francesco, Martino, Silvana, De Carli, Marco, Moschese, Viviana, Azzari, Chiara
Format: Artigo
Sprache:Inglês
Veröffentlicht: SAGE Publications 2016
Schlagworte:
Letters to the Editor
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5806788/
https://ncbi.nlm.nih.gov/pubmed/27927705
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0394632016681577
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge